These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31493244)

  • 1. Transdermal Delivery of Antipsychotics: Rationale and Current Status.
    Abruzzo A; Cerchiara T; Luppi B; Bigucci F
    CNS Drugs; 2019 Sep; 33(9):849-865. PubMed ID: 31493244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases.
    Ando K; Suzuki A; Yoshida H
    Respir Investig; 2023 Mar; 61(2):240-246. PubMed ID: 36791594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report.
    Sakai S; Morimoto Y; Matsuzaka Y; Nakano T; Kanegae S; Imamura A; Ozawa H
    Neuropsychopharmacol Rep; 2021 Sep; 41(3):440-443. PubMed ID: 34357702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia.
    El-Tokhy FS; Abdel-Mottaleb MMA; El-Ghany EA; Geneidi AS
    Int J Pharm; 2021 Oct; 608():121080. PubMed ID: 34506923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies.
    Vitorino C; Almeida A; Sousa J; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC; Pais A
    Eur J Pharm Biopharm; 2014 Feb; 86(2):133-44. PubMed ID: 24333401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Atypical Antipsychotics in the Treatment of Delirium: A Systematic Review of the Literature.
    Rivière J; van der Mast RC; Vandenberghe J; Van Den Eede F
    Psychosomatics; 2019; 60(1):18-26. PubMed ID: 30181002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone.
    Aggarwal G; Dhawan S; Hari Kumar SL
    Drug Dev Ind Pharm; 2013 Jan; 39(1):39-50. PubMed ID: 22335586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine.
    Aggarwal G; Dhawan S; Harikumar SL
    Pharm Dev Technol; 2013; 18(4):916-25. PubMed ID: 21913873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotics for delirium.
    Lonergan E; Britton AM; Luxenberg J; Wyller T
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005594. PubMed ID: 17443602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can lipid nanocarriers improve transdermal delivery of olanzapine?
    Iqbal N; Vitorino C; Taylor KM
    Pharm Dev Technol; 2017 Jun; 22(4):587-596. PubMed ID: 27876425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New generation antipsychotics for first episode schizophrenia.
    Rummel C; Hamann J; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal innovations in diabetes management.
    Rao R; Mahant S; Chhabra L; Nanda S
    Curr Diabetes Rev; 2014; 10(6):343-59. PubMed ID: 25418713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.